<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470376</url>
  </required_header>
  <id_info>
    <org_study_id>2015-006</org_study_id>
    <nct_id>NCT03470376</nct_id>
  </id_info>
  <brief_title>NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients</brief_title>
  <acronym>NU-TRY(HIV)</acronym>
  <official_title>Lipid-lowering and Vascular Effects of a Nutraceutical Combination in HIV-infected Patients on Stable Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of a nutraceutical combination (NC) containing low-dose monacolin K and berberine
      on lipid profile, proprotein convertase subtilisin/kexin type 9 (PCSK9), subclinical
      inflammation and arterial stiffness were investigated in human immunodeficiency virus
      (HIV)-infected patients receiving stable antiretroviral therapy (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a crossover interventional study of 26 HIV-infected patients on stable ART with low
      density lipoprotein cholesterol (LDL-C) &gt;100 mg/dL, not receiving any lipid-lowering
      treatment. After a 3-week lipid stabilization period with a standardized diet regimen, the
      effect of a 3-month oral NC containing red yeast rice-derived monacolin K 3 mg, berberine 500
      mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg vs no
      active treatment (noNC) was tested on plasma total cholesterol (TC), LDL-C, high density
      lipoprotein cholesterol (HDL-C), triglyceride, lipoprotein(a), PCSK9, high-sensitivity
      C-reactive protein (hsCRP) levels and aortic pulse wave velocity (aPWV).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2017</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>NC vs noNC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Patients names and allocation to arms was masked for outcomes assessors</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in LDL-C levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma LDL-C levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PCSK9 levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma PCSK9 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subclinical inflammation at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma hs-CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in arterial stiffness at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>aPWV</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in creatine phosphokinase (CPK) levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma CPK levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in aspartate transaminase (AST) levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma AST levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in alanine transaminase (ALT) levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>plasma ALT levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in CD4+ cell count at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>CD4+ cell count</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in HIV-1 RNA levels at 3 months</measure>
    <time_frame>3 months after treatment randomization</time_frame>
    <description>HIV-1 RNA levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Inflammation</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Nutraceutical combination (NC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No nutraceutical combination (noNC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients on standardized diet regimen without taking any NC</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutraceutical combination (NC)</intervention_name>
    <description>An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen</description>
    <arm_group_label>Nutraceutical combination (NC)</arm_group_label>
    <other_name>Armolipid Plus, Meda Pharma - Mylan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No nutraceutical combination (noNC)</intervention_name>
    <description>Prosecution of standardized diet regimen for 3 months</description>
    <arm_group_label>No nutraceutical combination (noNC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL-C &gt;100 mg/dL

          -  no history of cardiovascular disease

          -  stable ART for at least 6 months

        Exclusion Criteria:

          -  current or recent (â‰¤6 months) treatment with lipid-lowering drugs

          -  chronic kidney disease [estimated glomerular filtration rate (GFR) &lt;60 ml/min]

          -  liver impairment (AST and/or ALT &gt;3 times upper limit of normal)

          -  current pregnancy

          -  opportunistic infections within the past 3 months,

          -  having received an organ transplant/immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matteo Pirro, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Perugia, Italy</affiliation>
  </overall_official>
  <reference>
    <citation>Kelesidis T, Currier JS. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am. 2014 Sep;43(3):665-84. doi: 10.1016/j.ecl.2014.06.003. Review.</citation>
    <PMID>25169560</PMID>
  </reference>
  <reference>
    <citation>Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017 Feb 22;8:6-14. doi: 10.1016/j.jcte.2017.01.004. eCollection 2017 Jun. Review.</citation>
    <PMID>29067253</PMID>
  </reference>
  <reference>
    <citation>Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Curr Vasc Pharmacol. 2016;14(3):280-7.</citation>
    <PMID>26733388</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on &quot;Nutraceuticals for the treatment of hypercholesterolemia&quot; of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017 Jan;27(1):2-17. doi: 10.1016/j.numecd.2016.11.122. Epub 2016 Nov 22. Review.</citation>
    <PMID>27956024</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Mannarino MR, Ministrini S, Fallarino F, Lupattelli G, Bianconi V, Bagaglia F, Mannarino E. Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci Rep. 2016 Mar 23;6:23587. doi: 10.1038/srep23587.</citation>
    <PMID>27004462</PMID>
  </reference>
  <reference>
    <citation>Barrios V, Escobar C, Cicero AF, Burke D, Fasching P, Banach M, Bruckert E. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atheroscler Suppl. 2017 Feb;24:1-15. doi: 10.1016/j.atherosclerosissup.2016.10.003. Epub 2016 Dec 18. Review.</citation>
    <PMID>27998714</PMID>
  </reference>
  <reference>
    <citation>Pirro M, Mannarino MR, Bianconi V, Simental-MendÃ­a LE, Bagaglia F, Mannarino E, Sahebkar A. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016 Aug;110:76-88. doi: 10.1016/j.phrs.2016.04.021. Epub 2016 May 6. Review.</citation>
    <PMID>27157250</PMID>
  </reference>
  <reference>
    <citation>Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002 Feb;18(2):201-4.</citation>
    <PMID>11844656</PMID>
  </reference>
  <reference>
    <citation>Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007 May 22;49(20):2003-9. Epub 2007 May 4.</citation>
    <PMID>17512355</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Matteo Pirro</investigator_full_name>
    <investigator_title>Clinical Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>nutraceutical</keyword>
  <keyword>HIV</keyword>
  <keyword>PCSK9</keyword>
  <keyword>hsCRP</keyword>
  <keyword>stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Red yeast rice</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

